Peer Review reports
From: Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
| Original Submission | ||
|---|---|---|
| 28 Mar 2022 | Submitted | Original manuscript |
| 13 Apr 2022 | Author responded | Author comments - Junichi Yoshida |
| Resubmission - Version 2 | ||
| 13 Apr 2022 | Submitted | Manuscript version 2 |
| 4 Jul 2022 | Reviewed | Reviewer Report |
| 27 Jul 2022 | Reviewed | Reviewer Report |
| 5 Sep 2022 | Author responded | Author comments - Junichi Yoshida |
| Resubmission - Version 3 | ||
| 5 Sep 2022 | Submitted | Manuscript version 3 |
| 24 Oct 2022 | Author responded | Author comments - Junichi Yoshida |
| Resubmission - Version 4 | ||
| 24 Oct 2022 | Submitted | Manuscript version 4 |
| 28 Oct 2022 | Author responded | Author comments - Junichi Yoshida |
| Resubmission - Version 5 | ||
| 28 Oct 2022 | Submitted | Manuscript version 5 |
| 8 Nov 2022 | Author responded | Author comments - Junichi Yoshida |
| Resubmission - Version 6 | ||
| 8 Nov 2022 | Submitted | Manuscript version 6 |
| Publishing | ||
| 21 Nov 2022 | Editorially accepted | |
| 3 Dec 2022 | Article published | 10.1186/s12879-022-07889-z |
You can find further information about peer review here.